Literature DB >> 10579812

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base.

C McGuigan1, C J Yarnold, G Jones, S Velázquez, H Barucki, A Brancale, G Andrei, R Snoeck, E De Clercq, J Balzarini.   

Abstract

We herein report the discovery of an entirely new category of potent antiviral agents based on novel deoxynucleoside analogues with unusual bicyclic base moieties. Target structures, previously known as byproducts in Pd-catalyzed coupling of terminal alkynes with 5-iodo-nucleosides, are recognized herein for the first time to be potent and selective inhibitors of varicella-zoster virus (VZV) in vitro. As an unusual structure-activity relationship we noted the absolute requirement of a long alkyl side chain, with an optimum length of C(8)-C(10), for antiviral activity. We thus report the synthesis and characterization of a series of chain-modified analogues and their extensive in vitro evaluation. The lead compounds have a ca. 300-fold enhancement in anti-VZV activity over the reference compound acyclovir, with no detectable in vitro cytotoxicity. The novel structure of these compounds, coupled with their ease of synthesis, excellent antiviral profile, and promising physical properties, makes them of great interest for possible antiviral drug development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579812     DOI: 10.1021/jm990346o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Bromination at C-5 of Pyrimidine and C-8 of Purine Nucleosides with 1,3-Dibromo-5,5-dimethylhydantoin.

Authors:  Ramanjaneyulu Rayala; Stanislaw F Wnuk
Journal:  Tetrahedron Lett       Date:  2012-04-24       Impact factor: 2.415

Review 2.  Fluorescent analogs of biomolecular building blocks: design, properties, and applications.

Authors:  Renatus W Sinkeldam; Nicholas J Greco; Yitzhak Tor
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.

Authors:  Helen S Pentikis; Mark Matson; George Atiee; Brian Boehlecke; Jeff T Hutchins; Joseph M Patti; Geoffrey W Henson; Amy Morris
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

4.  Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.

Authors:  Graciela Andrei; Rebecca Sienaert; Chris McGuigan; Erik De Clercq; Jan Balzarini; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 6.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413

7.  Development of diversified methods for chemical modification of the 5,6-double bond of uracil derivatives depending on active methylene compounds.

Authors:  Hironao Sajiki; Yusuke Iida; Kanoko Ikawa; Yoshinari Sawama; Yasunari Monguchi; Yukio Kitade; Yoshifumi Maki; Hideo Inoue; Kosaku Hirota
Journal:  Molecules       Date:  2012-05-30       Impact factor: 4.411

Review 8.  The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold.

Authors:  Katherine L Seley-Radtke; Mary K Yates
Journal:  Antiviral Res       Date:  2018-04-10       Impact factor: 10.103

Review 9.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

10.  Novel 5'-Norcarbocyclic Derivatives of Bicyclic Pyrrolo- and Furano[2,3-d]Pyrimidine Nucleosides.

Authors:  Anna A Klimenko; Elena S Matyugina; Evgeniya B Logashenko; Pavel N Solyev; Marina A Zenkova; Sergey N Kochetkov; Anastasia L Khandazhinskaya
Journal:  Molecules       Date:  2018-10-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.